研究介紹

研究特色

基礎學科

吳介信老師

  1. 血管再阻塞(Restenosis)相關研究
    經皮穿腔血管成形術(percutaneous transluminal coronary angioplasty; PTCA)或稱為氣球擴張術(balloon angioplasty)是臨床上治療急性血管狹窄或阻塞的疾病(例如心肌梗塞)最常見的緊急治療措施。但是,在接受此項手術治療方法的患者中,約有30 ~ 50%的病人在半年內會有手術部位血管的再阻塞(restenosis)的情況發生。血管再阻塞主要是因為血管中具保護與調控角色的內皮細胞於手術過程中產生剝離,致使血管組織內的平滑肌細胞在血液中眾多刺激因子的共同作用下產生異常細胞增生與遷移(migration)以及細胞外基質(extracellular matrix)增加所造成的血管組織重塑(vascular tissue remodeling)現象。雖然,配合藥物塗層血管支架可降低血管再阻塞的發生率至10 ~ 30 %,但至今仍然無法有效解決此問題。因此,釐清血管再組塞的分子機制將有助於找尋預防血管再阻塞的新藥物標的。
  2. 抑制血管新生(Anti-angiogenesis)相關研究
    現今絕大多數的腫瘤治療藥物其研究及主要的作用機制仍使用非專一性標的(non-specific targeting)的方式來干擾細胞的生長複製亦或者促使細胞凋亡,而這樣的治療策略對於體力日趨耗弱的癌症病患來說無異是飲鴆止渴。另一方面,藥物治療過程中腫瘤細胞多重抗藥性(multiple drug-resistances)的產生亦是造成治療失敗的主要原因。因此,找尋其他更有效的治療策略與專一性的分子標的仍是目前迫切的研究課題。
    隨腫瘤塊的逐漸生長,其周邊的血管新生現象(neovascularization)日趨活躍,藉此新生的血管將提供更多的養份供給。因此,抑制血管新生作用將可阻斷腫瘤生長所需的養份,並減少腫瘤細胞藉由血液途徑轉移(metastasis)至身體他處的機率。而相較於腫瘤細胞,血管內皮細胞(vascular endothelial cells)具有相對穩定性與極低的對藥性產生。因此,抑制腫瘤誘發的血管新生作用之藥物開發與運用成為一個可行的的腫瘤治療策略。而目前約有80種抑制血管新生的抗腫瘤藥物已進行第一期或第二期的臨床實驗。在這些藥物中,一群是可抑制例如血管內皮生長因子(vascular endothelial growth factor; VEGF)接受器的小分子抑制劑或單株抗體(例如Avastin和Tarceva),而另一類則是內源性(endogenous)的血管新生抑制劑(例如angiostatin和endostatin)。雖然血管新生抑制劑研究結果顯示可有效延長病人的無病存活(progression-free survival),但仍有部分副作用存在。因此,找尋其他更佳的新生血管抑制劑仍是急需努力的方向。

李鳳琴老師

  1. 天然物成分的純化及抽取。
  2. 天然物成分及合成化合物之抗癌機制的探討。
  3. 與細胞凋亡訊號傳遞有關之機制。
  4. 蛋白質體學。

陸德齡老師
Our laboratory uses tumor cells and 3D culture renal tubulogenesis for assessing activities of many natural products that will be identified and/or purified in our colleague’s laboratories at School of Pharmacy, China Medical University. In addition, we will investigate the mechanisms leading to such effects of natural products. Therefore, we may identify the effects of natural products on renal tubulogenesis, or the effects of natural products on tumor cells. Other molecular projects in our colleague’s laboratories as well as our Departmental courses provide a rich environment for undergraduate and graduate students to learn the advanced cell biology and molecular biology.

許明志老師
我們研究主要是針對傳統中草藥或其它實驗室所提供的天然物抽出物、純化物,給與癌細胞,看其對於癌細胞的細胞毒殺性。並研究其誘導癌細胞凋亡、抑制癌細胞轉移、以及抑制血管新生的機轉探討。

鮑柏穎老師
Humans are unique individuals. Although all of us are genetically very similar, there are small differences in our DNA that are unique. These variations found in our genomes in combination with external environment factors affect each individual’s risk of getting or not getting certain diseases and working well or not working well by using the same treatment modality. Our research focuses on the development of genetic biomarkers for the diagnosis, prognosis, and prediction of treatment response of prostate cancer. Identification of these genetic variations will help researchers produce better predictive and diagnostic molecular tests and drugs, and will help physicians better select treatments and doses based on individual need.

Important News
1. Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, Lan YH, Lu TL, Lee HZ, Juang SH, Chen LM, Hsieh CJ, Huang SP*. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res 2011;17:928-36.
2. Huang CN, Huang SP, Pao JB, Chang TY, Lan YH, Lu TL, Lee HZ, Juang SH, Wu PP, Pu YS, Hsieh CJ, Bao BY*. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann Oncol 2011;10.1093/annonc/mdr264.
3. Huang CN, Huang SP, Pao JB, Hour TC, Chang TY, Lan YH, Lu TL, Lee HZ, Juang SH, Wu PP, Huang CY, Hsieh CJ, Bao BY*. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. J Intern Med 2011;10.1111/j.1365-2796.2011.02449.x.

 

←回前頁 ↑回頂層